JAK Inhibitors: What You Must Watch For - Infection and Blood Clot Risks

JAK Inhibitors: What You Must Watch For - Infection and Blood Clot Risks

When you're living with rheumatoid arthritis, psoriatic arthritis, or ulcerative colitis, finding a treatment that actually works can feel like a win. JAK inhibitors - drugs like JAK inhibitors tofacitinib, upadacitinib, and baricitinib - promised just that: faster relief than traditional biologics, with pills instead of injections. But since 2021, the story has changed. The FDA added a black box warning - the strongest possible - for these drugs because of two very real dangers: serious infections and blood clots. If you're considering or already taking one, you need to know what to watch for - not just what your doctor says, but what the data shows.

Why JAK Inhibitors Are Different

JAK inhibitors work inside your cells, blocking signals that cause inflammation. Unlike biologics that target proteins outside cells, these small molecules slip into your immune system’s control room and turn down the volume on cytokines. That’s why they work quickly. But that same mechanism is why they mess with more than just inflammation. JAK enzymes are involved in making blood cells, healing wounds, and even fighting viruses. Inhibit them too much, and you open the door to trouble.

The Infection Risk Is Real - And Common

Serious infections are the most reported side effect. In clinical trials and real-world use, about 1 in 20 people on JAK inhibitors develop a serious infection requiring hospitalization. That’s twice the rate seen with TNF inhibitors. The most common? Herpes zoster - shingles. Even if you got the vaccine, it’s not foolproof. One patient on Reddit shared how she got shingles within three months of starting tofacitinib, despite being vaccinated. She ended up in the hospital for five days.

Other infections include pneumonia, tuberculosis (TB), and fungal infections like histoplasmosis. Some people don’t even feel sick until it’s too late. A 68-year-old man on baricitinib thought he had the flu. He didn’t realize he had invasive aspergillosis - a rare lung fungus - until his oxygen levels crashed. He survived, but barely.

The FDA and EMA now require all patients to be screened for TB before starting. You also need up-to-date vaccines: pneumococcal, flu, and shingles. Live vaccines - like MMR or chickenpox - are a hard no while you’re on these drugs. If you’re due for one, get it at least four weeks before starting treatment.

Thrombosis: The Silent Killer You Can’t Ignore

Blood clots - specifically venous thromboembolism (VTE) - are the second big red flag. VTE includes deep vein thrombosis (DVT) and pulmonary embolism (PE). Both can kill. A 2022 analysis of over 126,000 patients found JAK inhibitors increased the odds of a clot by more than 2.3 times. The risk jumps even higher if you’re over 65, obese, smoke, or have had a clot before.

One woman on upadacitinib had a DVT in her calf after a long flight. She didn’t have pain at first - just swelling. By the time she went to the ER, the clot had traveled to her lung. Her doctor immediately stopped the drug. She’s now on blood thinners and switched to a different treatment.

The data shows JAK2 inhibitors - like tofacitinib and baricitinib - carry the highest clot risk because they interfere with platelet production. Upadacitinib, which is more selective for JAK1, seems to have a lower signal, but it’s still there. The FDA says: if you have any risk factors - obesity, history of clots, recent surgery, or use of estrogen - you shouldn’t start a JAK inhibitor unless there’s no other option.

Who Should Avoid These Drugs Altogether?

It’s not just about having one risk factor. It’s about the combination. The European Medicines Agency (EMA) says JAK inhibitors should only be used if:

• You’re under 65 and have no history of heart disease or clots
• You don’t smoke
• You don’t have cancer or a history of cancer
• You’ve tried and failed at least one TNF inhibitor or other biologic

If you’re over 65? The risk of death from any cause goes up 49% compared to TNF inhibitors, according to the ORAL Surveillance trial. That’s not a small number. Many rheumatologists now avoid prescribing JAK inhibitors to anyone over 60 unless they’re in a clinical trial or have no other options.

Monitoring Is Non-Negotiable

You can’t just take the pill and forget it. Regular blood tests are required. Every 4 to 8 weeks, you need a complete blood count to check for low white cells, red cells, or platelets. Lipid panels are also needed - JAK inhibitors raise cholesterol by 15-20% within weeks. That doesn’t mean you’re doomed, but it means you need to manage it with diet, exercise, or statins.

The American College of Rheumatology (ACR) recommends checking for signs of infection every visit: fever, cough, unusual fatigue, skin redness, or pain when urinating. If you develop any of these, stop the drug and call your doctor immediately. Don’t wait. Don’t try to tough it out.

What About the Newer JAK Inhibitors?

You might hear that newer drugs like upadacitinib or filgotinib are safer. There’s some truth to that. Upadacitinib is more selective for JAK1, which means less impact on blood cell production. Early data from the JAKARTA2 trial showed only 0.2 clots per 100 patient-years with upadacitinib - compared to 0.9 with tofacitinib. That’s promising.

But here’s the catch: we don’t have long-term data yet. The ORAL Surveillance trial followed patients for up to four years. Most newer studies are under a year. The FDA has mandated a 10-year safety study for all JAK inhibitors. Until then, assume all of them carry similar risks.

Real Patient Experience: The Trade-Off

A 52-year-old woman with severe psoriatic arthritis tried six biologics before switching to upadacitinib. Her skin cleared up in weeks. She went from using a cane to hiking again. But after six months, she got shingles. She recovered, but it scared her. She still takes the drug - but now she gets a shingles booster every year, checks her cholesterol monthly, and avoids long flights without moving her legs.

Her story isn’t rare. According to a 2023 Arthritis Foundation survey, 82% of patients who avoided infections and clots said the drug worked better than anything else they’d tried. But 57% still worry about blood clots. And 68% fear infection. That’s not fearmongering - that’s reality.

What Comes Next?

The field is moving toward more targeted drugs. TYK2 inhibitors - like deucravacitinib - are already approved for psoriasis and appear to have a cleaner safety profile. They don’t block JAK2 as much, so clot and infection risks may be lower. They’re not yet approved for rheumatoid arthritis or ulcerative colitis, but trials are underway.

For now, JAK inhibitors are still a tool - but only for the right patient. They’re not first-line. They’re not for everyone. They’re not a shortcut. They’re a calculated risk.

What to Do If You’re on a JAK Inhibitor

• Get your blood tests done on time - no skipping.
• Know the signs of infection: fever, chills, sore throat, cough, painful urination, red/swollen skin.
• Know the signs of a clot: swelling, warmth, or pain in one leg; sudden shortness of breath; chest pain; rapid heartbeat.
• If you’re over 65, smoke, or have a history of clots or heart disease - talk to your doctor about switching.
• Don’t ignore symptoms. If something feels off, call your rheumatologist - don’t wait for your next appointment.

What to Do If You’re Considering One

• Ask: Have I tried at least one TNF inhibitor or biologic first?
• Ask: Do I have any risk factors for clots or infection?
• Ask: Can I commit to monthly blood tests and regular check-ins?
• Ask: Is there a safer alternative - like a different biologic or a TYK2 inhibitor?

There’s no shame in choosing a slower, safer path. The goal isn’t just to reduce joint pain - it’s to live longer, healthier, and without unexpected hospitalizations.

Bottom Line: Safer Choices Exist

JAK inhibitors are powerful - but they’re not the only option. TNF inhibitors, IL-17 blockers, and now TYK2 inhibitors offer similar or better efficacy with fewer risks. If you’re young, healthy, and have no other options, a JAK inhibitor might still make sense. But if you’re over 60, have high blood pressure, smoke, or have had a clot before - you’re not a good candidate. There’s no glory in pushing through risk. The best treatment is the one that works without putting your life on the line.

About Author

Write a comment